Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting...
8 insider purchases on record · latest filing 2026-03-09.
Insiders have also filed 41 sale transactions at LYEL.